352 related articles for article (PubMed ID: 21749497)
1. Demyelination can proceed independently of axonal degradation during Wallerian degeneration in wlds mice.
Takada H; Yuasa S; Araki T
Eur J Neurosci; 2011 Aug; 34(4):531-7. PubMed ID: 21749497
[TBL] [Abstract][Full Text] [Related]
2. Wallerian degeneration and axonal regeneration after sciatic nerve crush are altered in ICAM-1-deficient mice.
Kirsch M; Campos Friz M; Vougioukas VI; Hofmann HD
Cell Tissue Res; 2009 Oct; 338(1):19-28. PubMed ID: 19657676
[TBL] [Abstract][Full Text] [Related]
3. The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves.
Beirowski B; Adalbert R; Wagner D; Grumme DS; Addicks K; Ribchester RR; Coleman MP
BMC Neurosci; 2005 Feb; 6():6. PubMed ID: 15686598
[TBL] [Abstract][Full Text] [Related]
4. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.
Meyer zu Horste G; Miesbach TA; Muller JI; Fledrich R; Stassart RM; Kieseier BC; Coleman MP; Sereda MW
Neurobiol Dis; 2011 Apr; 42(1):1-8. PubMed ID: 21168501
[TBL] [Abstract][Full Text] [Related]
5. WldS mice are resistant to paclitaxel (taxol) neuropathy.
Wang MS; Davis AA; Culver DG; Glass JD
Ann Neurol; 2002 Oct; 52(4):442-7. PubMed ID: 12325073
[TBL] [Abstract][Full Text] [Related]
6. The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice.
Mi W; Beirowski B; Gillingwater TH; Adalbert R; Wagner D; Grumme D; Osaka H; Conforti L; Arnhold S; Addicks K; Wada K; Ribchester RR; Coleman MP
Brain; 2005 Feb; 128(Pt 2):405-16. PubMed ID: 15644421
[TBL] [Abstract][Full Text] [Related]
7. Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice.
Beirowski B; Berek L; Adalbert R; Wagner D; Grumme DS; Addicks K; Ribchester RR; Coleman MP
J Neurosci Methods; 2004 Mar; 134(1):23-35. PubMed ID: 15102500
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of alpha-synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain.
Siebert H; Kahle PJ; Kramer ML; Isik T; Schlüter OM; Schulz-Schaeffer WJ; Brück W
J Neurochem; 2010 Aug; 114(4):1007-18. PubMed ID: 20524960
[TBL] [Abstract][Full Text] [Related]
9. Local axonal protection by WldS as revealed by conditional regulation of protein stability.
Wang JT; Medress ZA; Vargas ME; Barres BA
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10093-100. PubMed ID: 26209654
[TBL] [Abstract][Full Text] [Related]
10. Demyelination and axonal degeneration in Lewis rat experimental allergic neuritis depend on the myelin dosage.
Hahn AF; Feasby TE; Steele A; Lovgren DS; Berry J
Lab Invest; 1988 Jul; 59(1):115-25. PubMed ID: 3260639
[TBL] [Abstract][Full Text] [Related]
11. Enhanced axonal regeneration following combined demyelination plus schwann cell transplantation therapy in the injured adult spinal cord.
Keirstead HS; Morgan SV; Wilby MJ; Fawcett JW
Exp Neurol; 1999 Sep; 159(1):225-36. PubMed ID: 10486190
[TBL] [Abstract][Full Text] [Related]
12. Wlds protection distinguishes axon degeneration following injury from naturally occurring developmental pruning.
Hoopfer ED; McLaughlin T; Watts RJ; Schuldiner O; O'Leary DD; Luo L
Neuron; 2006 Jun; 50(6):883-95. PubMed ID: 16772170
[TBL] [Abstract][Full Text] [Related]
13. Local production of serum amyloid a is implicated in the induction of macrophage chemoattractants in Schwann cells during wallerian degeneration of peripheral nerves.
Jang SY; Shin YK; Lee HY; Park JY; Suh DJ; Kim JK; Bae YS; Park HT
Glia; 2012 Oct; 60(10):1619-28. PubMed ID: 22777957
[TBL] [Abstract][Full Text] [Related]
14. Wallerian demyelination: chronicle of a cellular cataclysm.
Tricaud N; Park HT
Cell Mol Life Sci; 2017 Nov; 74(22):4049-4057. PubMed ID: 28600652
[TBL] [Abstract][Full Text] [Related]
15. Consequences of slow Wallerian degeneration for regenerating motor and sensory axons.
Brown MC; Lunn ER; Perry VH
J Neurobiol; 1992 Jul; 23(5):521-36. PubMed ID: 1431835
[TBL] [Abstract][Full Text] [Related]
16. Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian degeneration.
Perrin FE; Lacroix S; Avilés-Trigueros M; David S
Brain; 2005 Apr; 128(Pt 4):854-66. PubMed ID: 15689362
[TBL] [Abstract][Full Text] [Related]
17. A rat model of slow Wallerian degeneration (WldS) with improved preservation of neuromuscular synapses.
Adalbert R; Gillingwater TH; Haley JE; Bridge K; Beirowski B; Berek L; Wagner D; Grumme D; Thomson D; Celik A; Addicks K; Ribchester RR; Coleman MP
Eur J Neurosci; 2005 Jan; 21(1):271-7. PubMed ID: 15654865
[TBL] [Abstract][Full Text] [Related]
18. Ropivacaine-induced peripheral nerve injection injury in the rodent model.
Whitlock EL; Brenner MJ; Fox IK; Moradzadeh A; Hunter DA; Mackinnon SE
Anesth Analg; 2010 Jul; 111(1):214-20. PubMed ID: 20442258
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cytokine expression profile during Wallerian degeneration of myelinated and unmyelinated peripheral axons.
Cheepudomwit T; Güzelsu E; Zhou C; Griffin JW; Höke A
Neurosci Lett; 2008 Jan; 430(3):230-5. PubMed ID: 18068300
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin M deposition in cutaneous nerves of anti-myelin-associated glycoprotein polyneuropathy patients correlates with axonal degeneration.
Stalder AK; Erne B; Reimann R; Renaud S; Fuhr P; Thomann S; Arnold A; Probst A; Schaeren-Wiemers N; Steck AJ
J Neuropathol Exp Neurol; 2009 Feb; 68(2):148-58. PubMed ID: 19151627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
